证券代码：688180 证券简称：君实生物 公告编号：临 2025-068 上海君实生物医药科技股份有限公司 关于使用暂时闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二） 产品品种 公司将按照相关规定严格控制风险，拟使用暂时闲置募集资金投资安全性高、 流动性好的保本型投资产品（包括但不限于通知存款、定期存款、协定存款、组 合存款、存单及结构性存款等），且该等产品不得用于质押，不用于以证券投资 为目的的投资行为。 （三） 决议有效期 自公司董事会审议通过之日起 12 个月内有效。 （四） 投资额度及期限 公司计划使用最高不超过人民币 24 亿元（包含本数）的暂时闲置募集资金 进行现金管理。根据募集资金使用情况以及公司经营情况，将暂时闲置募集资金 分笔按不同期限投资上述产品，最长期限不超过 12 个月。在前述额度和期限内， 资金可以循环滚动使用。 （五） 资金来源 上海君实生物医药科技股份有限公司（以下简称"公司"）于 2025 年 11 月 27 日召开第四届董事会第十五次会议，审议通过 ...

国泰海通证券股份有限公司 关于上海君实生物医药科技股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海君实生物医药科技股份有限公司（以下简称"君实生物"、"公司"或"发行人"） 2022 年度向特定对象发行 A 股股票的保荐人，根据《证券发行上市保荐业务管 理办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法 律法规和规范性文件的要求，就君实生物使用暂时闲置募集资金进行现金管理的 事项进行了审慎核查，并发表如下核查意见: 一、现金管理情况概述 （一）目的 为提高募集资金使用效率，合理利用部分暂时闲置募集资金，在确保不影响 募集资金投资项目建设和使用、募集资金安全且不变相改变募集资金用途的情况 下，增加公司资金收益，为公司及股东获取更多回报。 （二）产品品种 公司将按照相关规定严格控制风险，拟使用暂时闲置募集资金投资安全性高、 流动性好的保本型投资产品（包括但不限于通知存款、定期存款、协定存款、组 合存款、存单及结构性存款等），且该等产品不得 ...

Core Viewpoint - Junshi Biosciences (688180.SH) plans to utilize up to RMB 2.4 billion of temporarily idle raised funds for cash management [1] Group 1 - The company will invest the idle funds in different products based on the usage of raised funds and operational conditions [1] - The maximum investment period for these funds will not exceed 12 months [1] - The funds can be used in a rolling manner within the specified limit and timeframe [1]

Core Viewpoint - The company plans to utilize up to 2.4 billion yuan of temporarily idle raised funds for cash management, with a validity period of 12 months, allowing for rolling use of the funds [1] Group 1: Fund Management - The board of directors approved the use of idle funds from a specific A-share issuance in 2022, totaling 3.777 billion yuan raised, with a net amount of 3.745 billion yuan as of June 30, 2025 [1] - The company intends to invest in capital-preserving products, ensuring that the investment does not affect the implementation of fundraising projects [1] Group 2: Financial Strategy - The priority of the returns will be to replenish project funds and supplement working capital, with the funds to be returned to a designated account upon maturity [1]

Core Insights - Junshi Biosciences experienced a slight increase in stock price by 0.46% on November 26, with a trading volume of 294 million yuan [1] - The company reported a net financing purchase of 6.65 million yuan on the same day, indicating strong investor interest [1] Financing Overview - On November 26, Junshi Biosciences had a financing buy-in amount of 25.51 million yuan, with a total financing balance of 13.80 billion yuan, representing 4.86% of its market capitalization [1] - The financing balance is above the 80th percentile of the past year, indicating a high level of leverage [1] Short Selling Activity - On the same day, Junshi Biosciences saw a short selling repayment of 7,320 shares and a short selling amount of 1,623 shares, totaling 60,200 yuan in sales [1] - The remaining short selling volume was 30,390 shares, with a short selling balance of 11.27 million yuan, also above the 80th percentile of the past year [1] Company Profile - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06% [2] - The company recorded a net loss attributable to shareholders of 596 million yuan, which is a 35.72% increase compared to the previous year [2] Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period [2] - The average number of circulating shares per shareholder decreased by 12.96% to 21,361 shares [2]

消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液(皮下注射)(产品代号：JS001sc)对比 特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的 多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产 品的上市许可申请。 公开资料显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首 款进入III期临床研究阶段的国产抗 PD-1 单抗皮下制剂，有望给患者带来用药的便捷性。 智通财经APP获悉，君实生物(01877)再涨超5%，截至发稿，涨4.43%，报25.48港元，成交额4614.77万 港元。 ...

消息面上，君实生物宣布，由公司自主研发的特瑞普利单抗注射液(皮下注射)(产品代号：JS001sc)对比 特瑞普利单抗注射液(产品代号：JS001)联合化疗一线治疗复发或转移性非鳞状非小细胞肺癌(NSCLC)的 多中心、开放、随机对照Ⅲ期临床研究达到主要研究终点。君实生物计划将于近期向监管部门递交该产 品的上市许可申请。 公开资料显示，JS001sc是公司在已上市产品特瑞普利单抗注射液的基础上开发的皮下注射制剂，为首 款进入III期临床研究阶段的国产抗PD-1单抗皮下制剂，有望给患者带来用药的便捷性。 君实生物(01877)再涨超5%，截至发稿，涨4.43%，报25.48港元，成交额4614.77万港元。 ...

Core Viewpoint - Junshi Biosciences has shown a significant stock price increase of 37.80% year-to-date, despite recent fluctuations in the short term [2] Group 1: Stock Performance - As of November 26, Junshi Biosciences' stock price rose by 2.03% to 37.66 CNY per share, with a market capitalization of 38.665 billion CNY [1] - The stock has experienced a 1.76% increase over the last five trading days, a 3.34% decrease over the last 20 days, and a 16.63% decrease over the last 60 days [2] Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06% [2] - The company recorded a net loss attributable to shareholders of 596 million CNY, which is a 35.72% increase compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences increased by 15.17% to 35,900, while the average circulating shares per person decreased by 12.96% to 21,361 shares [2] - The top ten circulating shareholders include notable ETFs, with E Fund's ETF holding 19.3929 million shares, down by 2.8203 million shares from the previous period [3]

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

Market Overview - The biopharmaceutical sector increased by 0.83% on November 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3870.02, up 0.87%, while the Shenzhen Component Index closed at 12777.31, up 1.53% [1] Top Gainers in Biopharmaceutical Sector - Jinke (688670) closed at 25.75, up 19.99% with a trading volume of 92,200 shares [1] - Hualan Biological (301207) closed at 23.33, up 11.25% with a trading volume of 250,500 shares [1] - Saiseng Pharmaceutical (300485) closed at 11.95, up 5.19% with a trading volume of 168,000 shares [1] - Other notable gainers include Bohui Innovation (300318) at 6.84 (+3.32%) and Dongbao Biological (300239) at 5.72 (+3.25%) [1] Market Capital Flow - The biopharmaceutical sector saw a net inflow of 40.88 million yuan from institutional investors, while retail investors experienced a net outflow of 147 million yuan [2] - The sector's overall capital flow indicates a strong interest from institutional investors despite retail selling pressure [2] Individual Stock Capital Flow - Jinke (688670) had a net inflow of 39.66 million yuan from institutional investors, while retail investors showed a net outflow of 13.72 million yuan [3] - Other stocks like Watson Bio (300142) and Hualan Bio (002007) also experienced significant net inflows from institutional investors, indicating positive sentiment [3] - Conversely, stocks like Dongbao Biological (300239) and Bohui Innovation (300318) faced net outflows from retail investors, suggesting mixed investor sentiment [3]